Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolerability and safety of ANTIRIN nasal spray and drops in children with acute rhinitis
2006-005461-19Phase 3Completed
- Sponsor
- Zentiva
- Start
- Oct 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of xylometazoline + dexpanthenol in nasopharyngitis (4 arms), sponsored by Zentiva. Primary endpoints: Tolerability based on rhinitis symptom recording and Safety of ANTIRIN. Started Oct 2006; status: completed.
02
Drugs
xylometazoline + dexpanthenol
03
Conditions
nasopharyngitis
Beyond the preview
Go deeper on 2006-005461-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005461-19.